Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on April 5, 2012, regarding an event that occurred on April 2, 2012. The filing addresses the departure of a senior executive. Note: The request metadata lists "MADRIGAL PHARMACEUTICALS, INC.", but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Keizo Koya, Ph.D., who served as Senior Vice President, Drug Development. Dr. Koya informed the company of his intention to resign on April 2, 2012, with an effective date of April 6, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the executive departure.
Investor Verification Checklist
- Verify the effective date of Dr. Koya's resignation (April 6, 2012).
- Confirm the company's plan for replacing the Senior Vice President of Drug Development.
- Review subsequent filings for any impact on the company's drug development pipeline.
- Clarify the discrepancy between the request metadata (Madrigal Pharmaceuticals) and the filing registrant (Synta Pharmaceuticals).